These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1041 related articles for article (PubMed ID: 19444550)
41. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and Vind-Kezunovic S; Bouchelouche K; Ipsen P; Høyer S; Bell C; Bjerggaard Jensen J Eur Urol Focus; 2019 Jan; 5(1):90-96. PubMed ID: 28753817 [TBL] [Abstract][Full Text] [Related]
42. [ Li Y; Zhang Y; Guo Z; Hou P; Lv J; Ke M; Liu S; Li S; Yin W; He J; Wang X Cancer Imaging; 2024 Jun; 24(1):68. PubMed ID: 38831354 [TBL] [Abstract][Full Text] [Related]
43. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? Hellwig D; Graeter TP; Ukena D; Groeschel A; Sybrecht GW; Schaefers HJ; Kirsch CM J Nucl Med; 2007 Nov; 48(11):1761-6. PubMed ID: 17942814 [TBL] [Abstract][Full Text] [Related]
44. The diagnostic value of metabolic, morphological and heterogeneous parameters of 18F-FDG PET/CT in mediastinal lymph node metastasis of non-small cell lung cancer. Hua J; Li L; Liu L; Liu Q; Liu Y; Chen X Nucl Med Commun; 2021 Nov; 42(11):1247-1253. PubMed ID: 34269750 [TBL] [Abstract][Full Text] [Related]
45. Regional nodal staging with 18F-FDG PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging. Li M; Wu N; Liu Y; Zheng R; Liang Y; Zhang W; Zhao P Eur J Radiol; 2012 Aug; 81(8):1886-90. PubMed ID: 21511421 [TBL] [Abstract][Full Text] [Related]
46. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer. Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091 [TBL] [Abstract][Full Text] [Related]
47. Pattern and predictors of false positive lymph node involvement on positron emission tomography in patients with non-small cell lung cancer. Tamura M; Oda M; Matsumoto I; Waseda R; Watanabe G Thorac Cardiovasc Surg; 2012 Mar; 60(2):105-10. PubMed ID: 21789758 [TBL] [Abstract][Full Text] [Related]
48. Prediction of mediastinal lymph node metastasis based on Yin G; Song Y; Li X; Zhu L; Su Q; Dai D; Xu W Eur Radiol; 2021 Jun; 31(6):3983-3992. PubMed ID: 33201286 [TBL] [Abstract][Full Text] [Related]
49. Ratio between maximum standardized uptake value of N1 lymph nodes and tumor predicts N2 disease in patients with non-small cell lung cancer in 18F-FDG PET-CT scan. Honguero Martínez AF; García Jiménez MD; García Vicente A; López-Torres Hidalgo J; Colon MJ; van Gómez López O; Soriano Castrejón ÁM; León Atance P Rev Esp Med Nucl Imagen Mol; 2016; 35(3):159-64. PubMed ID: 26514322 [TBL] [Abstract][Full Text] [Related]
50. Early SUV Zhang J; Shi X; Xiao Y; Ma C; Cao G; Liu Y; Li Y Quant Imaging Med Surg; 2021 May; 11(5):1680-1691. PubMed ID: 33936956 [TBL] [Abstract][Full Text] [Related]
51. Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Bryant AS; Cerfolio RJ; Klemm KM; Ojha B Ann Thorac Surg; 2006 Aug; 82(2):417-22; discussion 422-3. PubMed ID: 16863739 [TBL] [Abstract][Full Text] [Related]
52. Dual-time-point FDG-PET for evaluation of lymph node metastasis in patients with non-small-cell lung cancer. Nishiyama Y; Yamamoto Y; Kimura N; Ishikawa S; Sasakawa Y; Ohkawa M Ann Nucl Med; 2008 May; 22(4):245-50. PubMed ID: 18535874 [TBL] [Abstract][Full Text] [Related]
53. Limited predictive value of dual-time-point F-18 FDG PET/CT for evaluation of pathologic N1 status in NSCLC patients. Kim SJ; Kim YK; Kim IJ; Kim YD; Lee MK Clin Nucl Med; 2011 Jun; 36(6):434-9. PubMed ID: 21552019 [TBL] [Abstract][Full Text] [Related]
54. Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3. Lee BE; Redwine J; Foster C; Abella E; Lown T; Lau D; Follette D J Thorac Cardiovasc Surg; 2008 Mar; 135(3):615-9. PubMed ID: 18329480 [TBL] [Abstract][Full Text] [Related]
55. FDG PET/CT for assessing the resectability of NSCLC patients with N2 disease after neoadjuvant therapy. Kremer R; Peysakhovich Y; Dan LF; Guralnik L; Kagna O; Nir RR; Bar-Shalom R Ann Nucl Med; 2016 Feb; 30(2):114-21. PubMed ID: 26613715 [TBL] [Abstract][Full Text] [Related]
56. Heterogeneity Analysis of (18)F-FDG Uptake in Differentiating Between Metastatic and Inflammatory Lymph Nodes in Adenocarcinoma of the Lung: Comparison with Other Parameters and its Application in a Clinical Setting. Budiawan H; Cheon GJ; Im HJ; Lee SJ; Paeng JC; Kang KW; Chung JK; Lee DS Nucl Med Mol Imaging; 2013 Dec; 47(4):232-41. PubMed ID: 24900118 [TBL] [Abstract][Full Text] [Related]
57. Serial changes of FDG uptake and diagnosis of suspected lung malignancy: a lesion-based analysis. Cheng G; Alavi A; Werner TJ; Del Bello CV; Akers SR Clin Nucl Med; 2014 Feb; 39(2):147-55. PubMed ID: 24368534 [TBL] [Abstract][Full Text] [Related]
58. The role of (18)F-FDG PET/CT for evaluation of metastatic mediastinal lymph nodes in patients with lung squamous-cell carcinoma or adenocarcinoma. Lu P; Sun Y; Sun Y; Yu L Lung Cancer; 2014 Jul; 85(1):53-8. PubMed ID: 24792334 [TBL] [Abstract][Full Text] [Related]
59. Correlation Between SUVmax and CT Radiomic Analysis Using Lymph Node Density in PET/CT-Based Lymph Node Staging. Giesel FL; Schneider F; Kratochwil C; Rath D; Moltz J; Holland-Letz T; Kauczor HU; Schwartz LH; Haberkorn U; Flechsig P J Nucl Med; 2017 Feb; 58(2):282-287. PubMed ID: 27660141 [TBL] [Abstract][Full Text] [Related]
60. Prognostic value of 18F-FDG uptake on positron emission tomography in patients with pathologic stage I non-small cell lung cancer. Um SW; Kim H; Koh WJ; Suh GY; Chung MP; Kwon OJ; Choi JY; Han J; Lee KS; Kim J J Thorac Oncol; 2009 Nov; 4(11):1331-6. PubMed ID: 19701106 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]